Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain

Objective: This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and predominant variant. Methods: A test-negative case-co...

Descripción completa

Detalles Bibliográficos
Autores: Jiménez-Sepúlveda N, Gras-Valentí P, Chico-Sánchez P, Castro-García JM, Ronda-Pérez E, Vanaclocha H, Peiró S, Burgos JS, Ana Berenguer, Navarro D, Sánchez-Payá J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:INCLIVA
Repositorio:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
OAI Identifier:oai:incliva.fundanetsuite.com:p18593
Acceso en línea:https://incliva.portalinvestigacion.com/publicaciones/18593
Access Level:acceso abierto
Palabra clave:COVID-19
SARS-CoV-2
SARS-CoV-2 vaccine
Case-control
Healthcare worker
SARS-CoV-2 variants
Infection prevention and control
id ES_dcf453030fef9350d5a4ca3fa41cddac
oai_identifier_str oai:incliva.fundanetsuite.com:p18593
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, SpainJiménez-Sepúlveda NGras-Valentí PChico-Sánchez PCastro-García JMRonda-Pérez EVanaclocha HPeiró SBurgos JSAna BerenguerNavarro DSánchez-Payá JCOVID-19SARS-CoV-2SARS-CoV-2 vaccineCase-controlHealthcare workerSARS-CoV-2 variantsInfection prevention and controlObjective: This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and predominant variant. Methods: A test-negative case-control design estimated vaccine effectiveness against symptomatic disease and hospitalization due to SARS-CoV-2. HCWs who underwent PCR or antigen testing for SARS-CoV-2 from January 2021 to March 2022 were included. Cases had a positive diagnostic test, while controls had negative tests. Adjusted vaccine effectiveness (aVE) was calculated using the formula: aVE = (1- Odds ratio) x 100. Results: During the Delta variant's predominance, aVE against infection within 12-120 days post-second dose was 64.8 % (BNT162b2) and 59.4 % (mRNA-1273), declining to 21.2 % and 42.2 %, respectively, after 120 days. For the Omicron variant, aVE within 12-120 days post-second dose was 61.1 % (BNT162b2) and 85.1 % (mRNA1273), decreasing to 36.7 % and 24.9 %, respectively, after 120 days. After a booster dose of mRNA-1273, aVE was 64.0 % (BNT162b2 recipients) and 65.9 % (initial mRNA-1273 recipients). Regardless of variant, aVE for hospitalization prevention after 2 doses was 87.0 % (BNT162b2) and 89.0 % (mRNA-1273). Conclusion: The administration of two doses of Moderna-mRNA-1273 against SARS-CoV-2 in HCWs proved to be highly effective in preventing infections and hospitalizations in the first 120 days after the second dose during the predominance of the Omicron variant. The decline in VE after 120 days since the administration of the second dose was significantly restored by the booster dose administration. This increase in VE was greater for the Pfizer vaccine. COVID-19 hospitalization prevention remained stable with both mRNA vaccines throughout the study period.ELSEVIER SCI LTD2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://incliva.portalinvestigacion.com/publicaciones/18593VaccineISSN: 0264410XISSNe: 18732518reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstname:INCLIVAInglésinfo:eu-repo/semantics/openAccessoai:incliva.fundanetsuite.com:p185932026-06-07T16:35:31Z
dc.title.none.fl_str_mv Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
title Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
spellingShingle Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
Jiménez-Sepúlveda N
COVID-19
SARS-CoV-2
SARS-CoV-2 vaccine
Case-control
Healthcare worker
SARS-CoV-2 variants
Infection prevention and control
title_short Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
title_full Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
title_fullStr Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
title_full_unstemmed Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
title_sort Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain
dc.creator.none.fl_str_mv Jiménez-Sepúlveda N
Gras-Valentí P
Chico-Sánchez P
Castro-García JM
Ronda-Pérez E
Vanaclocha H
Peiró S
Burgos JS
Ana Berenguer
Navarro D
Sánchez-Payá J
author Jiménez-Sepúlveda N
author_facet Jiménez-Sepúlveda N
Gras-Valentí P
Chico-Sánchez P
Castro-García JM
Ronda-Pérez E
Vanaclocha H
Peiró S
Burgos JS
Ana Berenguer
Navarro D
Sánchez-Payá J
author_role author
author2 Gras-Valentí P
Chico-Sánchez P
Castro-García JM
Ronda-Pérez E
Vanaclocha H
Peiró S
Burgos JS
Ana Berenguer
Navarro D
Sánchez-Payá J
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv COVID-19
SARS-CoV-2
SARS-CoV-2 vaccine
Case-control
Healthcare worker
SARS-CoV-2 variants
Infection prevention and control
topic COVID-19
SARS-CoV-2
SARS-CoV-2 vaccine
Case-control
Healthcare worker
SARS-CoV-2 variants
Infection prevention and control
description Objective: This study aimed to evaluate the effectiveness of SARS-CoV-2 mRNA vaccines in preventing infection and hospitalization among healthcare workers (HCWs) in the Valencian Community (Spain), considering vaccination timing, dose number, and predominant variant. Methods: A test-negative case-control design estimated vaccine effectiveness against symptomatic disease and hospitalization due to SARS-CoV-2. HCWs who underwent PCR or antigen testing for SARS-CoV-2 from January 2021 to March 2022 were included. Cases had a positive diagnostic test, while controls had negative tests. Adjusted vaccine effectiveness (aVE) was calculated using the formula: aVE = (1- Odds ratio) x 100. Results: During the Delta variant's predominance, aVE against infection within 12-120 days post-second dose was 64.8 % (BNT162b2) and 59.4 % (mRNA-1273), declining to 21.2 % and 42.2 %, respectively, after 120 days. For the Omicron variant, aVE within 12-120 days post-second dose was 61.1 % (BNT162b2) and 85.1 % (mRNA1273), decreasing to 36.7 % and 24.9 %, respectively, after 120 days. After a booster dose of mRNA-1273, aVE was 64.0 % (BNT162b2 recipients) and 65.9 % (initial mRNA-1273 recipients). Regardless of variant, aVE for hospitalization prevention after 2 doses was 87.0 % (BNT162b2) and 89.0 % (mRNA-1273). Conclusion: The administration of two doses of Moderna-mRNA-1273 against SARS-CoV-2 in HCWs proved to be highly effective in preventing infections and hospitalizations in the first 120 days after the second dose during the predominance of the Omicron variant. The decline in VE after 120 days since the administration of the second dose was significantly restored by the booster dose administration. This increase in VE was greater for the Pfizer vaccine. COVID-19 hospitalization prevention remained stable with both mRNA vaccines throughout the study period.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://incliva.portalinvestigacion.com/publicaciones/18593
url https://incliva.portalinvestigacion.com/publicaciones/18593
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER SCI LTD
publisher.none.fl_str_mv ELSEVIER SCI LTD
dc.source.none.fl_str_mv Vaccine
ISSN: 0264410X
ISSNe: 18732518
reponame:r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname:INCLIVA
instname_str INCLIVA
reponame_str r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
collection r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421815990845440
score 15,81155

Similares en LA Referencia